This study will test the COVID-19 vaccine candidate AZD1222 to investigate its safety,tolerability and capability of boosting immune responses both in the blood and the lungwhen administered to the respiratory tract, in volunteers previously vaccinated byintramuscular COVID-19 vaccination. Using standardised methods, we will measure immuneresponses in the blood, nose and lower airway and compare with data from ongoing clinicaltrials of intramuscular vaccination. Thus, we will show the effect of the delivery methodand provide the critical information required to begin further clinical trials to showthe efficacy of this needle-free vaccination strategy for booster vaccination.

On 11 February 2020, the International Committee for the Classification of Viruses namedthe disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia(coronavirus disease 2019, COVID-19). Due to the characteristics of livermicrocirculation disturbance and immune function disorder in patients with chronic liverdiseases (such as immune liver disease, chronic hepatitis C, liver cirrhosis, livercancer, etc.), those patients has a higher risk of infection than the general populationduring the epidemic period. More attention should be paid to personal protection anddisease prevention. Vaccination of COVID-19 vaccine can effectively prevent COVID-19virus infection and delay or prevent patients from developing into critical illness andreduce mortality. To evaluate the safety and effectiveness of COVID-19 vaccine in thosepatients with chronic liver diseases, and to guide the COVID-19 vaccination morescientifically, reasonably and effectively, this study was carried out.

A randomized, double-blind, placebo -controlled, phase IIb clinical trial to evaluate theefficacy, safety and immunogenicity of one or two doses of Recombinant Novel CoronavirusVaccine (Adenovirus Type 5 Vector) in adults 18 years of age and older, living with HIV,on stable treatment, and virologically suppressed for at least 6 monthsProtocol number: FH-58

This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trialof the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of theexperimental vaccine in healthy population aged 3 to 17 years.

This study is a randomized, double-blinded, and placebo controlled phase Ⅱ clinical trialof the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of theexperimental vaccine in healthy population aged 3 to 17 years.

A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety andImmunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNAVaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health

This is an observer-blind, randomized study which aims to assess the immune response andthe safety of two different approved vaccines for first and second dose in healthyadults.

Preliminary data suggest that inactivated vaccine-induced neutralizing antibodies againstSARS-CoV-2 decrease at six months after vaccination. Observational, unpublished data alsoindicate that vaccine effectiveness against Covid-19 wanes over time. Thus, theinvestigators aimed to determine the reactogenicity, safety, and immunogenicity of ahomologous or heterologous booster of SARS-CoV-2 vaccines among people already immunizedwith an inactivated SARS-CoV-2 vaccine. The study focuses on the elderly population andhealthcare workers.

The purpose of this double-blind, randomized, controlled study is to assessimmunogenicity and safety of 202-CoV at multiple dose levels, administered as 2injections (i.m) at 28 days apart in adult subjects 18 years of age and above.

Randomized, open, multicenter, collaborative and adaptive non-inferiority trial toevaluate the immunogenicity and reactogenicity of the heterologous vaccination schedulesmade up of the combination of vaccines available in Argentina (Sputnik-V, AstraZeneca,Sinopharm and Moderna); and to compare the immunogenicity and reactogenicity ofheterologous and homologous vaccination schedules.